Gout - Adenuric(R) (Febuxostat) Receives Marketing Authorisation In The European Union
May 15th 2008Drug InformationGout
Ipsen (Paris:IPN) announced that the European Commission granted marketing authorisation for Adenuric® (febuxostat) for the treatment of chronic hyperuricaemia in gout. Adenuric® thus pioneers the first major treatment alternative for gout, a severe debilitating disease, for more than 40 years.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
